U.S. Markets closed

UGI Corp (UGI) Q2 Earnings Miss Estimates, Revenues Beat

Zacks Equity Research

UGI Corporation UGI delivered second-quarter fiscal 2019 adjusted earnings of $1.43 per share, which missed the Zacks Consensus Estimate of $1.58 by 9.49%. The bottom line declined 15.4% from the prior-year quarter’s figure of $1.69.

Excluding one-time items, the company generated GAAP earnings of $1.38 in the reported quarter compared with the year-ago quarter’s figure of $1.57.

Revenues

Revenues of $2,606 million in the quarter surpassed the Zacks Consensus Estimate of $2,591 million by 0.57%. However, the top line declined 7.3% from the year-ago quarter’s figure of $2,812 million.

UGI Corporation Price, Consensus and EPS Surprise

 

UGI Corporation Price, Consensus and EPS Surprise | UGI Corporation Quote

 

Operational Highlights

Total operating income amounted to $538.8 million compared with $591 million in the year-ago quarter.

Total interest expenses amounted to $61 million, up 5% from the prior-year quarter’s tally.

Warmer-than-normal weather during the critical heating months of January and February led to decline in retail volume in AmeriGas,UGI International and Midstream & Marketing operations.

Guidance

The company reaffirmed fiscal 2019 EPS guidance in the range of $2.40-$2.60.

Zacks Rank

UGI currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Other Releases

MDU Resources Group Inc MDU delivered first-quarter 2019 operating earnings of 21 cents per share, which missed the Zacks Consensus Estimate of 24 cents by 12.5%.

ONE Gas, Inc OGSgenerated first-quarter 2019 operating earnings of $1.76 per share, which beat the Zacks Consensus Estimate of $1.73 by 1.7%.

ONEOK Inc OKE came up with first-quarter 2019 operating earnings of 81 cents per share, which beat the Zacks Consensus Estimate of 73 cents by 10.96%.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ONEOK, Inc. (OKE) : Free Stock Analysis Report
 
UGI Corporation (UGI) : Free Stock Analysis Report
 
ONE Gas, Inc. (OGS) : Free Stock Analysis Report
 
MDU Resources Group, Inc. (MDU) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research